ArticleJournal of lipid research2017
Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport.
Article in Journal of lipid research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- The Gut Microbiome Affects Atherosclerosis by Regulating Reverse Cholesterol Transport.Journal of cardiovascular translational research · 2024Review
- PLTP deficiency-mediated atherosclerosis regression could be related to sphinogosine-1-phosphate reduction.Atherosclerosis · 2022Article
- High-density lipoproteins, reverse cholesterol transport and atherogenesis.Nature reviews. Cardiology · 2021Review
- Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases.Life (Basel, Switzerland) · 2021Review
- Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis.Atherosclerosis · 2021Article
- The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis.Current atherosclerosis reports · 2021Review
- Impact of Phospholipid Transfer Protein in Lipid Metabolism and Cardiovascular Diseases.Advances in experimental medicine and biology · 2020Review
- Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.Atherosclerosis · 2019Article
- Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis.Journal of lipid research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Phospholipid transfer protein (PLTP) may affect macrophage reverse cholesterol transport (mRCT) through its role in the metabolism of HDL. Ex vivo cholesterol efflux capacity and in vivo mRCT were assessed in PLTP deletion and PLTP overexpression mice. PLTP deletion mice had reduced HDL mass and cholesterol efflux capacity, but unchanged in vivo mRCT. To directly compare the effects of PLTP overexpression and deletion on mRCT, human
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.